S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
Log in

NASDAQ:BVXV - BIONDVAX PHARMA/S Stock Price, Forecast & News

$6.12
-0.08 (-1.29 %)
(As of 12/11/2019 04:00 PM ET)
Today's Range
$6.07
Now: $6.12
$6.20
50-Day Range
$5.29
MA: $5.65
$6.20
52-Week Range
$3.51
Now: $6.12
$7.26
Volume9,598 shs
Average Volume6,107 shs
Market Capitalization$39.99 million
P/E RatioN/A
Dividend YieldN/A
Beta1.15
BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Ness Ziona, Israel.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BVXV
CUSIPN/A
Phone972-8930-2529

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($1.27) per share

Profitability

Net Income$-23,410,000.00

Miscellaneous

Employees14
Market Cap$39.99 million
Next Earnings Date5/5/2020 (Estimated)
OptionableNot Optionable

Receive BVXV News and Ratings via Email

Sign-up to receive the latest news and ratings for BVXV and its competitors with MarketBeat's FREE daily newsletter.


BIONDVAX PHARMA/S (NASDAQ:BVXV) Frequently Asked Questions

What is BIONDVAX PHARMA/S's stock symbol?

BIONDVAX PHARMA/S trades on the NASDAQ under the ticker symbol "BVXV."

When is BIONDVAX PHARMA/S's next earnings date?

BIONDVAX PHARMA/S is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for BIONDVAX PHARMA/S.

Has BIONDVAX PHARMA/S been receiving favorable news coverage?

Media stories about BVXV stock have been trending somewhat negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BIONDVAX PHARMA/S earned a media sentiment score of -1.1 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for BIONDVAX PHARMA/S.

Are investors shorting BIONDVAX PHARMA/S?

BIONDVAX PHARMA/S saw a drop in short interest in November. As of November 29th, there was short interest totalling 1,900 shares, a drop of 24.0% from the November 14th total of 2,500 shares. Based on an average trading volume of 4,700 shares, the short-interest ratio is presently 0.4 days. Approximately 0.0% of the company's shares are short sold. View BIONDVAX PHARMA/S's Current Options Chain.

Who are some of BIONDVAX PHARMA/S's key competitors?

What other stocks do shareholders of BIONDVAX PHARMA/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BIONDVAX PHARMA/S investors own include AbbVie (ABBV), BIOLINERX LTD/S (BLRX), Exelixis (EXEL), Gilead Sciences (GILD), Pluristem Therapeutics (PSTI), Agilent Technologies (A), Akari Therapeutics (AKTX), Celgene (CELG), Neurocrine Biosciences (NBIX) and Allergan (AGN).

Who are BIONDVAX PHARMA/S's key executives?

BIONDVAX PHARMA/S's management team includes the folowing people:
  • Dr. Ron Babecoff, Co-Founder, CEO, Pres & Director (Age 57)
  • Mr. Uri Ben-Or CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 49)
  • Dr. Tamar Ben Yedidia, Chief Scientific Officer (Age 55)
  • Dr. Shimon Hassin, Chief Operating Officer
  • Mr. Elad Mark, Head of Site & Process Devel.

When did BIONDVAX PHARMA/S IPO?

(BVXV) raised $10 million in an initial public offering on Tuesday, May 12th 2015. The company issued 1,400,000 shares at a price of $7.32 per share. Aegis Capital Corp served as the underwriter for the IPO.

How do I buy shares of BIONDVAX PHARMA/S?

Shares of BVXV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BIONDVAX PHARMA/S's stock price today?

One share of BVXV stock can currently be purchased for approximately $6.12.

How big of a company is BIONDVAX PHARMA/S?

BIONDVAX PHARMA/S has a market capitalization of $39.99 million. The company earns $-23,410,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis. BIONDVAX PHARMA/S employs 14 workers across the globe.View Additional Information About BIONDVAX PHARMA/S.

What is BIONDVAX PHARMA/S's official website?

The official website for BIONDVAX PHARMA/S is http://www.biondvax.com/.

How can I contact BIONDVAX PHARMA/S?

BIONDVAX PHARMA/S's mailing address is Jerusalem BioPark 2nd floor Hadassah Ein Kerem Campus, Jerusalem L3, 74036. The company can be reached via phone at 972-8930-2529 or via email at [email protected]


MarketBeat Community Rating for BIONDVAX PHARMA/S (NASDAQ BVXV)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  149 (Vote Outperform)
Underperform Votes:  170 (Vote Underperform)
Total Votes:  319
MarketBeat's community ratings are surveys of what our community members think about BIONDVAX PHARMA/S and other stocks. Vote "Outperform" if you believe BVXV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BVXV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel